Media Center

News Releases

KYTHERA Biopharmaceuticals To Present at the Bank of America Merrill Lynch 2015 Health Care Conference
May 8, 2015

Westlake Village, Calif., May 8, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the Bank of America Merrill Lynch 2015 Health Care Conference. Event:      Bank of America Merrill Lynch 2015 Health Care Conference Date:       Thursday, May 14, 2015 Time:…

KYTHERA Biopharmaceuticals Releases First Quarter 2015 Operating Results and Progress Update
May 7, 2015

Company Well Positioned for Commercial Launch of KYBELLA™ (deoxycholic acid) Injection Westlake Village, Calif., May 7, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today reported financial results for the first quarter of 2015, and provided an update on recent accomplishments. “KYTHERA recently achieved our most significant milestone to date, that of receiving FDA approval of KYBELLA™,…

KYTHERA Biopharmaceuticals To Release First Quarter 2015 Operating Results 
April 30, 2015

Westlake Village, Calif., April 30, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced it will release its first quarter 2015 operating results and will host an investor call and webcast at 4:30 p.m. ET on Thursday, May 7, 2015. Individuals interested in participating in the call should dial (877) 344-3890 (U.S. and Canada) or…

KYTHERA Biopharmaceuticals Announces FDA Approval of KYBELLA(TM) (also known as ATX-101) — First and Only Submental Contouring Injectable Drug
April 29, 2015

KYBELLA(TM) (deoxycholic acid) Injection Significantly Improves Submental Fullness, or “Double Chin” WESTLAKE VILLAGE, Calif., April 29, 2015 (GLOBE NEWSWIRE) — KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) announced today that the U.S. Food and Drug Administration (FDA) has approved KYBELLA™, also known as ATX-101, “for improvement in the appearance of moderate to severe convexity or fullness associated with submental…

KYTHERA Biopharmaceuticals Announces 2015 Outlook Call
March 19, 2015

Westlake Village, Calif., March 19, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced it will host a 2015 Outlook investor call and webcast at 4:30 p.m. ET on Thursday, March 26, 2015. Individuals interested in participating in the call should dial (877) 344-3890 (U.S. and Canada) or (760) 666-3770 (international) using conference ID number…

KYTHERA Biopharmaceuticals Announces Closing of Public Offering and Exercise of Underwriters’ Over-Allotment Option
March 16, 2015

Westlake Village, Calif., March 16, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced the closing of its underwritten public offering of 2,994,793 shares of its common stock at a price to the public of $48.00 per share for gross proceeds of approximately $143.8 million, which includes the exercise in full by the underwriters of their…

KYTHERA Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
March 10, 2015

Westlake Village, Calif., March 10, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced the pricing of its underwritten public offering of 2,604,168 shares of its common stock at a price to the public of $48.00 per share, before underwriting discounts and commissions and expenses of the offering, for gross proceeds of approximately $125 million. All…

KYTHERA Biopharmaceuticals Announces Proposed Public Offering of Common Stock
March 9, 2015

Westlake Village, Calif., March 9, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced it has commenced an underwritten public offering of $125 million of shares of its common stock. All of the shares of the common stock to be sold in the offering will be offered by KYTHERA. KYTHERA intends to use the net proceeds…

KYTHERA Biopharmaceuticals Announces FDA Advisory Committee Unanimously (17-0) Recommends to Approve ATX-101 (deoxycholic acid) Injection to Improve the Appearance of Moderate to Severe Submental Fullness
March 9, 2015

Westlake Village, Calif., March 9, 2015 — KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) announced today that the U.S. Food and Drug Administration’s (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee has voted unanimously to support the approval of ATX-101 (deoxycholic acid) injection for improvement in the appearance of moderate to severe convexity or fullness associated with submental…

KYTHERA Biopharmaceuticals Announces 2014 Operating Results
March 2, 2015

Westlake Village, Calif., March 2, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today reported financial results for its quarter and year ended December 31, 2014, and provided an update on recent accomplishments. “Last year KYTHERA achieved many milestones and this year we continue our upward momentum. Most notably, we filed our New Drug Application for ATX-101…